Wednesday, 3 November, 2021 - 15:00
Manufacturing grants for medical innovations
A device to predict kidney disease and a diagnostic imaging tool for cancer surgery are among the innovations awarded a share of $450,000 for commercialisation.
SynGenis works with highly experienced synthesis chemists and other supporting staff to provide high quality oligonucleotides, and supports diagnostic & therapeutic development for research organisations and businesses including pharma industries in Australia and around the world.
Established in late 2020, SynGenis was the brainchild of world-renowned oligonucleotide chemical biologist Associate Professor Rakesh Veedu.
Contact Details
Unit 2-14 Brodie-Hall Drive
,
BENTLEY
WA
6102
08 6249 4415
info@syngenis.com
